Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer

NCT02567409 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

87

Enrollment

NIH

Sponsor class

Conditions

Metastatic Bladder Urothelial Carcinoma
Metastatic Renal Pelvis and Ureter Urothelial Carcinoma
Metastatic Ureter Urothelial Carcinoma
Stage IV Bladder Urothelial Carcinoma AJCC v7

Interventions

DRUG: Berzosertib
DRUG: Cisplatin
DRUG: Gemcitabine Hydrochloride

Sponsor

National Cancer Institute (NCI)